Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.63 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | RCE1 | Q9Y256 | 3/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.50 |
| ▸ | VDR | P11473 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | P4HB | P07237 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5512077 | 0.87 | VDR (0.58) | CFTRGOPCKMT2ATDP1MEN1 | |
| SCHEMBL21103619 | 0.85 | ALDH1A1 (0.53) | CFTRGOPCKMT2ATDP1MEN1 | |
| SCHEMBL2392990 | 0.84 | KMT2A (0.51) | CFTRGOPCKMT2AMEN1MAPT | |
| SCHEMBL5512074 | 0.84 | MAPT (0.52) | CFTRGOPCKMT2AMEN1MAPT | |
| SCHEMBL27874471 | 0.84 | KMT2A (0.53) | CFTRGOPCKMT2AMEN1MAPT | |
| SCHEMBL11562639 | 0.84 | KMT2A (0.71) | CFTRGOPCKMT2AMEN1MAPT | |
| SCHEMBL28359204 | 0.84 | KMT2A (0.77) | CFTRGOPCKMT2AMEN1MAPT | |
| SCHEMBL28707659 | 0.84 | KMT2A (0.51) | CFTRGOPCKMT2AMEN1MAPT | |
| SCHEMBL29665053 | 0.84 | MAPT (0.52) | CFTRGOPCKMT2ATDP1MEN1 | |
| SCHEMBL28503562 | 0.82 | KMT2A (0.50) | CFTRGOPCKMT2ATDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4188353-A1 | NOVEL USES | Intra-Cellular Therapies, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| CN-114174555-A | Compositions comprising silacycloalkanes for deposition of silicon-containing films and methods of use thereof | 弗萨姆材料美国有限责任公司 | 2022-03-11 | — | — | CN | claimed |
| WO-2022026417-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| CN-109336887-B | Benzimidazole chiral heterocyclic compound and preparation method and application thereof | 中山大学 | 2021-12-17 | — | — | CN | claimed |
| EP-3802545-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| EP-1294695-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2001085694-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-15 | — | — | WO | claimed |
| EP-0812259-A4 | ELECTROLUMINESCENT DEVICE | POLAROID CORP (US) | 1998-04-15 | — | — | EP | claimed |
| EP-0812259-A1 | ELECTROLUMINESCENT DEVICE | POLAROID CORPORATION (US) | 1997-12-17 | — | — | EP | claimed |
| WO-1996021559-A1 | ELECTROLUMINESCENT DEVICE | POLAROID CORPORATION (US) | 1996-07-18 | — | — | WO | claimed |
| CN-119977850-A | Urea derivative containing aryl sulfonamide structure, and preparation method and application thereof | 沈阳药科大学 | 2025-05-13 | — | — | CN | disclosed |
| CN-115843293-B | Tricyclic compound, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119118894-A | TRPV4 receptor ligands | 犹他大学研究基金会 | 2024-12-13 | — | — | CN | disclosed |
| EP-4188353-A1 | NOVEL USES | Intra-Cellular Therapies, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023061294-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 再鼎医药(上海)有限公司 | 2023-04-20 | — | — | WO | disclosed |
| US-20050070723-A1 | Process for the synthesis of a CPLA2 inhibitor | WYETH HOLDINGS CORPORATION (US) | 2005-03-31 | — | — | US | disclosed |
| EP-1294695-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001085694-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
| US-4352696-A | Process and composition | THE UPJOHN COMPANY (US) | 1982-10-05 | — | — | US | disclosed |
| US-4257995-A | STORAGE STABILITY | THE UPJOHN COMPANY (US) | 1981-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070723-A1 | Process for the synthesis of a CPLA2 inhibitor | PLAA, PLA2G4A, PLA2G12A | CFTR 4521/4885GOPC 3426/4885KMT2A 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.